Zacks Research Has Optimistic Outlook of ResMed Q3 Earnings

ResMed Inc. (NYSE:RMD) – Analysts at Zacks Research upped their Q3 2025 earnings per share (EPS) estimates for ResMed in a research report issued on Wednesday, February 19th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $2.33 per share for the quarter, up from their previous estimate of $2.30. The consensus estimate for ResMed’s current full-year earnings is $9.44 per share. Zacks Research also issued estimates for ResMed’s Q4 2025 earnings at $2.39 EPS, FY2025 earnings at $9.35 EPS, Q1 2026 earnings at $2.28 EPS, Q2 2026 earnings at $2.37 EPS, Q3 2026 earnings at $2.50 EPS, FY2026 earnings at $9.63 EPS, Q1 2027 earnings at $2.49 EPS, Q2 2027 earnings at $2.60 EPS and FY2027 earnings at $10.61 EPS.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%.

RMD has been the topic of several other reports. Robert W. Baird raised their target price on ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Friday, January 31st. JPMorgan Chase & Co. raised their price objective on ResMed from $270.00 to $286.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. The Goldman Sachs Group started coverage on ResMed in a research report on Thursday, January 16th. They issued a “buy” rating for the company. Finally, Royal Bank of Canada lifted their target price on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $244.73.

ResMed Stock Performance

Shares of NYSE:RMD opened at $232.89 on Friday. The company has a market cap of $34.20 billion, a P/E ratio of 27.50, a PEG ratio of 1.55 and a beta of 0.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. ResMed has a one year low of $170.56 and a one year high of $263.05. The business’s 50-day simple moving average is $237.57 and its 200 day simple moving average is $238.96.

Institutional Trading of ResMed

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of ResMed by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider’s stock worth $4,156,089,000 after acquiring an additional 160,590 shares during the period. State Street Corp increased its holdings in ResMed by 1.9% during the 3rd quarter. State Street Corp now owns 6,261,633 shares of the medical equipment provider’s stock valued at $1,528,590,000 after purchasing an additional 116,918 shares in the last quarter. Geode Capital Management LLC increased its holdings in ResMed by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider’s stock valued at $899,860,000 after purchasing an additional 85,270 shares in the last quarter. Invesco Ltd. increased its stake in shares of ResMed by 32.2% in the 4th quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider’s stock valued at $531,706,000 after buying an additional 566,046 shares during the period. Finally, Northern Trust Corp increased its stake in shares of ResMed by 20.6% in the 4th quarter. Northern Trust Corp now owns 1,702,590 shares of the medical equipment provider’s stock valued at $389,365,000 after buying an additional 290,664 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Buying and Selling at ResMed

In other news, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction on Friday, February 7th. The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the transaction, the chief executive officer now owns 455,472 shares in the company, valued at approximately $107,842,105.44. The trade was a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total value of $491,300.00. Following the completion of the transaction, the director now owns 81,218 shares in the company, valued at $19,951,201.70. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,147 shares of company stock valued at $2,905,745 in the last quarter. Corporate insiders own 0.71% of the company’s stock.

ResMed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.91%. The ex-dividend date is Thursday, February 13th. ResMed’s payout ratio is currently 25.03%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.